Bioventus Names Allison London Brown New VP of Global Marketing
Bioventus Names Allison London Brown New VP of Global Marketing
DURHAM, N.C. – February 14, 2014 – Bioventus, a leader in active orthopedic healing, today announced that Allison London Brown has joined the company as its new Vice President of Global Marketing. London Brown is based in the company’s Durham headquarters and reports directly to Bioventus CEO Anthony Bihl.
In the role, London Brown is responsible for developing global strategic marketing plans, including evaluating new market opportunities, and for management of the current product portfolio. She oversees the tactical implementation of U.S. and International marketing plans, including product positioning, product launch planning and sales support. She also provides leadership for business strategy, external communications, professional affairs and medical education.
“Allison comes to Bioventus with a wealth of experience – not only in marketing, but also as a former CEO and COO of healthcare organizations,” Bihl said. “She is known for building brands and driving revenue in the medical device, technology and pharmaceutical industries. I’m excited to have her on our leadership team.”
During London Brown’s 17-year career, she has launched more than 80 new products, brands and services for leading global healthcare companies. She worked for 10 years at the Johnson & Johnson family of companies, two years at GE Healthcare and two years at Healthways Inc. Her most recent experience includes CEO of Aegis Women’s Health Technologies, Chief Operating Officer/Chief Commercial Officer at Stanley Healthcare Solutions (division of Stanley/Black & Decker), and a Senior Advisor, Board Member and Co-Founder of various start-up companies.
London Brown is also a published author, accomplished presenter and holder of five patents. She holds a Bachelor of Science from Auburn University, a Masters of Science from North Carolina State University and a Masters of Business Administration with Honors from Temple University.
About Bioventus
Bioventus is a biologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company’s innovative products include market-leading devices, therapies and diagnostics that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine, and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com or follow the company on Facebook (www.facebook.com/bioventus) or Twitter (@BioventusGlobal or www.twitter.com/BioventusGlobal).
-
Bioventus Acquires DUROLANE Assets from Galderma
Bioventus Acquires DUROLANE Assets from Galderma
DURHAM, N.C. – February 4, 2014 – Bioventus, a leader in active orthopaedic healing, today announced that it has entered into an agreement with Galderma to acquire the International assets for DUROLANE®, a product that helps relieve the pain of osteoarthritis (OA) in a variety of joints.* Bioventus previously had exclusive global distribution rights and served as the distributor for DUROLANE in Europe, Canada and Australia.
With the new agreement, Galderma will continue to serve as the manufacturer of DUROLANE; however, Bioventus now controls all future plans and distribution for the product outside of the United States. Financial terms of the agreement were not disclosed.
“DUROLANE has been an invaluable product to numerous OA sufferers throughout the world,” said Anthony Bihl, CEO of Bioventus. “We see growth potential and new market opportunities for the product, and determined that controlling the assets puts us in the best position to realize these opportunities.”
Treating patients for more than 12 years, DUROLANE is the original single-injection joint-fluid treatment and contains high levels of non-animal stabilized hyaluronic acid (NASHA®) technology. Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. It is injected into indicated joints* affected by mild to moderate OA to help relieve pain, restore lubrication and improve joint function. The product is available in two formats – DUROLANE (3ml) for mild to moderate knee or hip OA, and DUROLANE SJ (1ml) for indicated* smaller joints.
About Bioventus
Bioventus is a biologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company’s innovative products include market-leading devices, therapies and diagnostics that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine, and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com or follow the company on Facebook (www.facebook.com/bioventus) or Twitter (@BioventusGlobal or www.twitter.com/BioventusGlobal).
*Indications
DUROLANE: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate arthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes. DUROLANE is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.
DUROLANE SJ: Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes. DUROLANE SJ is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.
DUROLANE and NASHA are registered trademarks of Galderma S.A.
